Based on a review of the data and discussion, the panel consensus was not to make changes to the current recommendations on this page.

Based on the review of the data in the noted reference, the panel consensus was to include Fam-trastuzumab deruxtecan-nxki for HER2 overexpression positive adenocarcinoma as a second-line or subsequent therapy option for Unresectable Locally Advanced, Recurrent, or Metastatic Disease. This is a category 2A, preferred recommendation.


Based on the review of the data, the panel consensus was to include under preferred regimens for second-line or subsequent therapy for Unresectable Locally Advanced, Recurrent, or Metastatic Disease the following dose schedule: Fam-trastuzumab deruxtecan-nxki (for HER2 overexpression positive adenocarcinoma) 6.4 mg/kg IV on Day 1, cycled every 21 days with corresponding footnote: “Fam-trastuzumab deruxtecan-nxki is approved for metastatic HER2-positive breast cancer at a different dose of 5.4 mg/kg IV on Day 1, cycled every 21 days”